[ad_1] Novartis names Sreeman Balineni as new Executive Director We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok [ad_2] Source link
[ad_1] Novartis opens new radioligand therapy manufacturing facility in California We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok [ad_2] Source link
[ad_1] Novartis Scemblix receives positive CHMP opinion for newly diagnosed CML in adults We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok [ad_2] Source link
[ad_1] Novartis Rhapsido gets USFDA nod for chronic spontaneous urticaria We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok [ad_2] Source link
[ad_1] Novartis commences tender offer to buy Tourmaline Bio We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok [ad_2] Source link
[ad_1] Novartis, Monte Rosa Therapeutics join hands for Degraders to treat Immune-mediated diseases We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok [ad_2] Source link
[ad_1] Novartis to buy Tourmaline Bio for USD 1.4 billion We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok [ad_2] Source link
[ad_1] Novartis, Argo Biopharma expand strategic alliance with USD 5.2 billion Cardiovascular drugs deal We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok [ad_2] Source link
[ad_1] Novartis, Arrowhead strike upto USD 2 billion deal for neuromuscular therapy license We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok [ad_2] Source link
[ad_1] Novartis Leqvio shows statistically significant, clinically meaningful early LDL-C goal achievement with less muscle pain We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok [ad_2] Source link